<DOC>
	<DOCNO>NCT01076985</DOCNO>
	<brief_summary>This non-interventional , post-marketing observational study conduct obtain safety data use lopinavir/ritonavir ( Kaletra ) , clinical practice , pregnant woman child Japan .</brief_summary>
	<brief_title>Special Investigation Kaletra Pregnant Women</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>All pregnant woman receive Kaletra treatment HIV infection eligible study Contraindications accord Package Insert : Patients history hypersensitivity ingredient Kaletra Patients receive pimozide , cisapride , ergotamine tartrate , dihydroergotamine mesylate , ergometrine maleate , methylergometrine maleate , midazolam , triazolam , vardenafil hydrochloride hydrate , boriconazol</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Human Immunodeficiency Virus</keyword>
</DOC>